Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Merck's Investigational Lipid-Modifier, CORDAPTIVE™ , Positively Affected Key Lipid Parameters With Less Flushing, In Data from Phase III Study
- WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today Phase III clinical study results with CORDAPTIVETM (ER niacin/ laropiprant), an investigational compound containing Merck-developed extended-release niacin and laropiprant - a novel flushing pathway inhibitor, in which CORDAPTIVE reduced LDL-cholesterol (LDL-C) levels, increased HDL-cholesterol (HDL-C) levels and reduced triglyceride levels...
- Research articles 2007-09-02
- Merck Announces FDA Acceptance of NDA for CORDAPTIVE™ , Formerly Known as MK-0524A, an Investigational Lipid-Modifier
- WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the New Drug Application NDA for CORDAPTIVE[TM] (ER niacin/laropiprant), formerly known as MK-0524A, has been accepted for standard review by the U.S. Food and Drug Administration FDA. Merck anticipates FDA action in the second quarter of 2008. The Company...
- Research articles 2007-08-29
- FDA to New Drugs: It's Hammer Time
- Wonder no further whether the recent litany of drug-safety problems would make the Food and Drug Administration more cautious about approving new drugs. In just the past four days, the agency has thrown some serious sand into the industry's drug-development works, delaying or derailing three separate programs of widely varying...
- Blog posts 2008-04-29
Additional Resources
- Is Merck Hanging Schering Out to Dry on Vytorin?
- A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
- Blog posts 2008-04-23
- Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III Study
- CHICAGO -- Patients with dyslipidemia treated with CORDAPTIVE[TM] (extended release niacin/laropiprant) reported significantly less flushing and significantly fewer discontinuations due to flushing than patients treated with Niaspan[TM] Abbott. Niacin is a proven lipid-modifying agent; however, a major barrier to its use is the side effect of flushing. These Phase III...
- Research articles 2008-03-31
- Merck's Investigational Extended-Release Niacin/Laropiprant Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study
- Study Supports Development of CORDAPTIVE Coadministered with Simvastatin
- Research articles 2007-11-05
- Merck reassigns Gardasil exec
- Sometimes in business journalism we overlook the fact that every deal, every drug approval, every sales decline isn't some abstract event, but one engineered and caused by, lamented or celebrated, by individual people. When the story is a layoff, the impact on individuals is clear. Not so much a "Complete...
- News items 2009-08-07
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
